News on improved reading ability in new published trial 2017
Dr Mats Johnson presents Equazen eye q clinical trial at Swiss Neuro-paediatrics Association annual meeting showing improved reading ability.
Omega-3 and omega-6 fatty acids are important membrane components of the brain. Accumulating evidence from epidemiological, biochemical and intervention studies indicate that suboptimal dietary intake of omega-3 and omega-6 fatty acids can have detrimental effects on children’s cognitive development and behaviour.
A recent randomised, double-blind, placebo-controlled trial in 9-year-old mainstream schoolchildren in Sweden was conducted to evaluate the effect of Omega 3/6 fatty acids on reading in children.
The study, known as the LOGOS trial has been presented by its author, Dr. Johnson, at the the annual meeting of Swiss Neuro-paediatrics Association, Solothurn, Switzerland.
Over 150 Doctors, mainly Neuropsychiatric specialists and Paediatricians, attended the 2- day meeting.
The study was conducted on 154 children over a period of 6 months on 2 phases of 3 months each, and the outcomes measured the Logos test battery which is a computerised reading test based on the theory that word decoding is a central function for reading ability.
Results have shown that Equazen eye q significantly improves reading ability, naming time, phonologic decoding time, visual analysis time, reading speed per word and phonologic decoding time per word when compared to placebo.
Key Findings
The study showed that:
- eye q improves reading ability in mainstream schoolchildren
- eye q is well tolerated and has a high compliance similar to that of placebo
More information: